CJC 1295 DAC and ipamorelin dosage varies by research protocol. Compare typical ranges, timing, and safety notes before considering any peptide stack.
There is no FDA-approved CJC 1295 DAC and ipamorelin dosage for humans because neither peptide is approved for medical use in the United States. In research settings, common protocols pair 1–2 mg of CJC-1295 DAC once weekly with 100–300 mcg of ipamorelin taken one to three times daily. Those numbers are experimental starting points from published studies and anecdotal reports, not clinical recommendations.
What CJC-1295 and Ipamorelin Are
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog. It comes in two forms: CJC-1295 with DAC, which binds to albumin and lasts for days, and CJC-1295 without DAC, also called mod GRF (1-29), which clears much faster.
Ipamorelin is a selective growth hormone secretagogue. It mimics ghrelin to stimulate growth hormone release from the pituitary gland.
CJC-1295 DAC is not FDA-approved for human use in the United States. Ipamorelin is not FDA-approved for human use in the United States. Both are sold as research chemicals, and their sale for human consumption is illegal.
Typical CJC 1295 DAC and Ipamorelin Dosage Ranges in Research
Most literature and online protocols describe a once-weekly CJC-1295 DAC injection combined with daily ipamorelin. A common ratio is 1 mg to 2 mg of CJC-1295 DAC per week and 100 mcg to 300 mcg of ipamorelin per dose.
Some users split the ipamorelin dose into two or three smaller injections. Others take a single daily dose before bed. Timing is often based on natural growth hormone pulses, which peak during deep sleep.
No peptide dosage should be started without medical supervision. Self-dosing with research chemicals carries risks of contamination, inaccurate dosing, and unknown long-term effects.
| Protocol element | Common research range | Frequency | Notes |
|---|---|---|---|
| CJC-1295 DAC | 1–2 mg per week | Once weekly | Long half-life due to DAC binding. |
| Ipamorelin | 100–300 mcg per dose | 1–3 times daily | Often taken before sleep or post-workout. |
| Combined stack | CJC-1295 DAC weekly plus ipamorelin daily | Weekly + daily | Doses are not established as safe or effective. |
CJC-1295 With DAC vs Without DAC When Stacking With Ipamorelin
The choice between CJC-1295 with DAC and CJC-1295 without DAC changes the injection schedule. CJC-1295 DAC stays active for about 6–8 days, so it is usually injected once per week. CJC-1295 without DAC has a half-life of roughly 30 minutes, so research protocols often inject it two to three times daily.
When people discuss cjc-1295 dac and ipamorelin dosage, they usually mean the weekly-plus-daily schedule. When they discuss cjc 1295 without dac and ipamorelin dosage, they usually mean a more frequent schedule where both peptides are taken together multiple times per day.
Some blends combine CJC-1295 without DAC and ipamorelin in a single vial. A cjc 1295 no dac and ipamorelin blend is typically sold as a 10 mg total powder, with equal parts of each peptide.
| Form | Half-life | Typical frequency with ipamorelin | Key consideration |
|---|---|---|---|
| CJC-1295 with DAC | About 6–8 days | Once weekly CJC + daily ipamorelin | Longer exposure, slower clearance. |
| CJC-1295 without DAC | About 30 minutes | 2–3 times daily with ipamorelin | More injections, faster peak. |
| 10 mg blend (no DAC + ipamorelin) | Short | 1–3 times daily | Fixed ratio may not fit individual needs. |
How Researchers and Users Time the Stack
Growth hormone release follows a circadian rhythm. Most natural secretion happens during slow-wave sleep, so many protocols place ipamorelin at bedtime. Some also add a dose after training or in the morning.
Food can blunt the growth hormone response. Many protocols recommend injecting on an empty stomach and waiting 20–30 minutes before eating.
For CJC-1295 DAC, timing is less critical because of the long half-life. Users often pick a consistent day each week to keep blood levels stable.
A common question is how cjc-1295 ipamorelin dosage differs when the DAC form is used. The total weekly CJC-1295 DAC amount is usually higher than the daily CJC-1295 without DAC amount, but the ipamorelin dose stays in the same 100–300 mcg range per injection.
Safety, Side Effects, and Legal Status
Neither peptide is approved by the FDA for any human indication. That means there are no standard doses, no pharmacy-grade quality guarantees, and no long-term safety data from large human trials.
Reported side effects from growth hormone-releasing peptides include:
- Injection site reactions such as redness, pain, or swelling.
- Headache, flushing, or dizziness.
- Increased hunger or changes in blood sugar.
- Water retention, joint pain, or numbness.
- Fatigue or lethargy in some users.
Growth hormone excess can cause serious problems, including insulin resistance, swelling of the hands and feet, and joint pain. People with cancer, diabetes, or pituitary disorders should avoid these compounds unless a doctor specifically prescribes them.
Anyone considering CJC-1295 or ipamorelin should consult a licensed healthcare professional first.
What to Ask a Healthcare Professional
Because dosing is not standardized, a doctor or pharmacist can help evaluate risks, interactions, and monitoring needs. Useful questions include:
- Are there FDA-approved alternatives for my goal?
- What baseline labs should I have before considering growth hormone peptides?
- What symptoms would signal a serious reaction?
- How would this interact with my current medications?
Self-experimentation with unapproved peptides can cause harm, and no online dosage chart replaces individualized medical advice.
Bottom Line
The most commonly cited research range for CJC 1295 DAC and ipamorelin dosage is 1–2 mg of CJC-1295 DAC weekly plus 100–300 mcg of ipamorelin one to three times daily. CJC-1295 without DAC requires more frequent injections, often two to three times per day.
These numbers are not approved medical doses. They come from early research, anecdotal reports, and vendor materials. There is no safe or effective human dose of CJC-1295 or ipamorelin that has been established by the FDA.
Frequently Asked Questions
What is the typical CJC-1295 DAC and ipamorelin dosage?
Research protocols often use 1–2 mg of CJC-1295 DAC once weekly with 100–300 mcg of ipamorelin one to three times daily. These are experimental ranges, not FDA-approved doses. Anyone considering them should speak with a healthcare professional.
Is CJC-1295 with DAC or without DAC better for stacking with ipamorelin?
CJC-1295 with DAC lasts about 6–8 days, so it is usually injected weekly. CJC-1295 without DAC lasts about 30 minutes, so it is typically injected two to three times daily with ipamorelin. Neither form is FDA-approved for human use, and better depends on the research question rather than proven human outcomes.
What side effects are linked to CJC-1295 and ipamorelin?
Reported side effects include injection site reactions, headache, flushing, increased hunger, water retention, joint pain, and numbness. Growth hormone excess can also cause insulin resistance and swelling. Because these peptides are unapproved, long-term safety data in humans are limited.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.